Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 37 Guo Xue Rd., Chengdu, 610041, Sichuan Province, China.
Department of Day Surgery Centre, West China Hospital, Sichuan University, Chengdu, China.
Obes Surg. 2019 Jun;29(6):1954-1964. doi: 10.1007/s11695-019-03817-4.
Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) used for super obesity (SO) and super super obesity (SSO) remain controversial. The meta-analysis was to summarize the evidence.
We searched in MEDLINE and PubMed for studies concerning RYGB and SG for SO or SSO and pooled complication, percentage excess weight loss (%EWL), and resolution of comorbidities.
Twelve studies were identified. RYGB achieved higher %EWL at 12 months, but no significant difference at 24 months. Resolution of diabetes mellitus and dyslipidemia reached a statistical significance; however, there was no significant difference in hypertension.
RYGB was superior in %EWL for SSO and SO at 12 months. However, regarding at 24 months, RYGB was equal to SG, which is from a meta-analysis and cannot be seen as a definitive conclusion.
用于治疗超级肥胖症(SO)和超级超级肥胖症(SSO)的 Roux-en-Y 胃旁路术(RYGB)和袖状胃切除术(SG)仍存在争议。本荟萃分析旨在总结相关证据。
我们在 MEDLINE 和 PubMed 中检索了关于 RYGB 和 SG 治疗 SO 或 SSO 的研究,并对并发症、超重减轻百分比(%EWL)和合并症的缓解情况进行了汇总。
共纳入了 12 项研究。RYGB 在 12 个月时的超重减轻百分比更高,但在 24 个月时无显著差异。糖尿病和血脂异常的缓解达到了统计学意义;然而,高血压并无显著差异。
在 12 个月时,RYGB 在 SSO 和 SO 的超重减轻百分比方面优于 SG。然而,关于 24 个月的结果,RYGB 与 SG 相当,这是基于荟萃分析得出的,不能视为明确的结论。